Nanoparticles for treatment of bovine Staphylococcus aureus mastitis

Drug Deliv. 2020 Dec;27(1):292-308. doi: 10.1080/10717544.2020.1724209.

Abstract

Staphylococcus aureus (S. aureus) is one of the most important zoonotic bacterial pathogens, infecting human beings and a wide range of animals, in particular, dairy cattle. Globally. S. aureus causing bovine mastitis is one of the biggest problems and an economic burden facing the dairy industry with a strong negative impact on animal welfare, productivity, and food safety. Furthermore, its smart pathogenesis, including facultative intracellular parasitism, increasingly serious antimicrobial resistance, and biofilm formation, make it challenging to be treated by conventional therapy. Therefore, the development of nanoparticles, especially liposomes, polymeric nanoparticles, solid lipid nanoparticles, nanogels, and inorganic nanoparticles, are gaining traction and excellent tools for overcoming the therapeutic difficulty accompanied by S. aureus mastitis. Therefore, in this review, the current progress and challenges of nanoparticles in enhancing the S. aureus mastitis therapy are focused stepwise. Firstly, the S. aureus treatment difficulties by the antimicrobial drugs are analyzed. Secondly, the advantages of nanoparticles in the treatment of S. aureus mastitis, including improving the penetration and accumulation of their payload drugs intracellular, decreasing the antimicrobial resistance, and preventing the biofilm formation, are also summarized. Thirdly, the progression of different types from the nanoparticles for controlling the S. aureus mastitis are provided. Finally, the difficulties that need to be solved, and future prospects of nanoparticles for S. aureus mastitis treatment are highlighted. This review will provide the readers with enough information about the challenges of the nanosystem to help them to design and fabricate more efficient nanoformulations against S. aureus infections.

Keywords: S. aureus; drug delivery; mastitis; nanogel; nanoparticles; resistance.

Publication types

  • Review

MeSH terms

  • Animals
  • Anti-Bacterial Agents / administration & dosage*
  • Anti-Bacterial Agents / pharmacology
  • Biofilms / drug effects
  • Cattle
  • Drug Resistance, Bacterial
  • Female
  • Humans
  • Mastitis, Bovine / drug therapy*
  • Mastitis, Bovine / microbiology
  • Nanoparticles
  • Staphylococcal Infections / drug therapy*
  • Staphylococcal Infections / veterinary
  • Staphylococcus aureus / drug effects

Substances

  • Anti-Bacterial Agents

Grants and funding

This work was supported by the National Natural Science Foundation of China [grant no. 31772797].